LAUSR

(HR (95% CI) = 0.600 (0.428-0.841)) . Multivariate Cox analysis with the interaction between treatment group and sCD30 level showed an increased risk of experiencing an mPFS event with ABVD and sCD30 >median (interaction p = 0.025) when adjusted by other prognostic factors (Ann Arbor stage, IPS and ENI). Similar trends were observed with the exploratory ad-hoc TARC analysis. No new safety signals were reported in subgroups with elevated sCD30 or TARC levels. Conclusions: Preliminary adhoc analysis indicates that ABVD treated patients do not perform as well with elevated baseline sCD30 and TARC levels. A+AVD treated patients perform well regardless of levels of these poor prognostic markers. Prospective studies need to be conducted in order to further validate these findings. If validated, these biomarkers may help identify patient populations that could benefit from more effectively targeted therapy.